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Long-term therapy with the macrolide antibiotic erythromycin was shown to alter the clinical course of diﬀuse panbronchiolitis in
the late 1980s. Since that time, macrolides have been found to have a large number of anti-inﬂammatory properties in addition to
being antimicrobials. These observations provided the rationale for many studies performed to assess the usefulness of macrolides
in other inﬂammatory diseases including skin and hair disorders, such as rosacea, psoriasis, pityriasis rosea, alopecia areata,
bullous pemphigoid, and pityriasis lichenoides. This paper summarizes a collection of clinical studies and case reports dealing
with the potential beneﬁts of macrolides antibiotics in the treatment of selected dermatoses which have primarily been classiﬁed
as noninfectious and demonstrating their potential for being disease-modifying agents.
1.Introduction
The term “macrolide” encompasses a diverse family of
unrelated compounds with large macrolactam rings. The
macrolide antibiotics consist of 14-, 15-, and 16-member
macrolactam ring antimicrobials. Erythromycin A, the pro-
totype macrolide antibiotic was isolated from a Philippine
soil sample in the 1940s and was ﬁrst marketed in 1952
as an alternative therapy to beta lactam agents for the
treatmentof infectionswithGram-positive cocci.Duringthe
1990s clarithromycin, roxithromycin, and azithromycin were
introduced. Macrolide antibiotics inhibit RNA-dependent
protein synthesis by reversibly binding to the 50S ribosomal
subunit of a susceptible microorganism [1].
Macrolides are widely used to treat infections of soft
tissues and of the respiratory tract due to their eﬃcacy
against Gram-negative and Gram-positive bacteria, includ-
ing intracellular germs such as Chlamydia and Legionella [2–
4]. They are considered safe and easily tolerable. Their main
side eﬀects are nausea, vomiting, diarrhea, and abdominal
pain, which become more evident when erythromycin
is used in place of the other macrolides [5]. Mounting
evidence suggests that macrolide antibiotics have both anti-
inﬂammatory and immune-modulatory properties and are
thus beneﬁcial to chronic pulmonary diseases such as diﬀuse
panbronchiolitis, cystic ﬁbrosis, asthma, and bronchiecta-
sis. These properties were suspected upon the realization
that erythromycin decreased the need for corticosteroids
in asthma treatment [6]. It must be pointed out that
immune modulation is the suppression of inﬂammation and
immune hyperactivation without causing immune depres-
sion (immunosuppression) [7].
Macrolides antibiotics have been shown to modify host
functions apart from the antimicrobial potency. They may
directly inﬂuence phagocyte and lymphocyte function as
well as chemotaxis. Eﬀects on the generation and release of
various cytokines involved in the inﬂammatory process have
been studied both in vivo and in vitro [8].
Interest in the immunomodulatory eﬀects of macrolides
began in the 1960s with the observation that the 14-member
antibiotic, troleandomycin, was an eﬀective “steroid-
sparing” agent when used to treat patients with severe
asthma [9]. It has been more than 20 years since the
immunomodulatory eﬀects of macrolides were accepted as a
standard of care for the treatment of diﬀuse panbronchiolitis
(DPB) in Japan [10]. Erythromycin and clarithromycin are
also widely used in Japan for the therapy of sinusitis and
chronic obstructive pulmonary disease (COPD) [11]. In2 Mediators of Inﬂammation
more recent years, azithromycin has been widely adopted
as immunomodulatory agents for the treatment of cystic
ﬁbrosis (CF) and bronchiectasis.
The anti-inﬂammatory eﬀects of macrolides are sig-
niﬁcant. The historical change in the natural course of
diﬀuse panbronchiolitis (DPB), a fatal disorder of the
airways, following the introduction of erythromycin in its
treatment has focused attention of researchers on the anti-
inﬂammatory properties of macrolides. The clinical impact
on diﬀuse panbronchiolitis (DPB) has improved 10-year
survival from 12% to more than 90% for these patients [12].
The immunomodulatory activity of macrolides has been a
source of mechanistic research as well as clinical research in
non-DPB inﬂammatory airway disease. Suppression of neu-
trophilicinﬂammationoftheairwayshasbeendemonstrated
as the most robust immunomodulatory response from 14-
and 15-membered ring macrolides [13].
Macrolide antibiotics are known for their eﬃcacy in
treating acute airway infections, but just as importantly,
they are also eﬀective anti-inﬂammatory agents. Their anti-
inﬂammatory properties have been studied most thoroughly
in chronic inﬂammatory airway diseases, particularly dif-
fuse panbronchiolitis (DPB). Erythromycin, azithromycin,
clarithromycin, and roxithromycin inhibit chemotaxis and
inﬁltration of neutrophils into the airway and, subsequently,
decrease mucus secretion. Mucus formation, a signiﬁcant
cause of morbidity and mortality in patients with chronic
airway inﬂammation, is directly inhibited by macrolides and
suppressed by decreased inﬂammation in the airway. The
mechanisms of action for the anti-inﬂammatory properties
of the macrolides are clearly multifactorial. Macrolides
inhibit the production of many proinﬂammatory cytokines,
such as interleukin (IL)-1, IL-6, IL-8, and tumor necrosis
factor-alpha, perhaps by suppressing the transcription factor
nuclear factor-kappa B or activator protein-1. Inhibition
of cytokine production has been seen in vitro and also
in bronchoalveolar lavage ﬂuid, which contains less IL-
8 and fewer neutrophils after treatment with macrolides.
Macrolides also inhibit formation of leukotriene B4, which
attracts neutrophils, and inhibit the release of superoxide
anion by neutrophils that may be present in the airway.
An important aspect of inﬂammation is extravasation of
neutrophils into the tissues. Macrolides block formation
of adhesion molecules necessary for neutrophil migration.
Together, these anti-inﬂammatory eﬀects result in improved
pulmonaryfunctionsandfewerairwayinfections.Inpatients
with DPB, the anti-inﬂammatory eﬀects lead to a signiﬁcant
i n c r e a s ei ns u r v i v a l .T h e s ee ﬀects might be pharmacological
functions of the macrolide itself, independent of antibiotic
eﬀects. Apart from antibacterial eﬀects, macrolides have
eﬀects on neutrophil function (decreased oxidant produc-
tion, apoptosis) and on the production of cytokines involved
in the inﬂammation cascade (decreased production of IL-1,
IL-6, IL-8, and TNF and increased production of IL-10 and,
possibly, IL-4). With regard to T lymphocytes, erythromycin
(EM) and its derivatives inhibit T-lymphocyte proliferation
and induce T-lymphocyte apoptosis [14, 15].
In this paper, we present a collection of clinical studies
and case reports dealing with the potential beneﬁts of
macrolides antibiotics in the treatment of selected der-
matoses which have primarily been classiﬁed as noninfec-
tious. A comprehensive search in the PubMed/MEDLINE
and Embase databases was performed. We examined the
eligible literature. Studies that dealt with the eﬀects of
macrolides as anti-inﬂammatory and immune-modulator in
skin and hair disorders were included.
(A) Macrolides and Intractable Rosacea. Rosacea is a com-
mon cutaneous disorder which occurs most frequently
in light-skinned, middle-aged women. There are variable
cutaneous signs of rosacea such as ﬂushing, erythema,
telangiectasia, edema, papules, and pustules [16].
Conventional treatment of rosacea is based on a combi-
nation of systemic and topical antibiotics. Since the 1950s,
tetracycline and erythromycin are the most commonly used
oral antibiotics [17]. The therapeutic activity of commonly
used antimicrobials including tetracycline, doxycycline has
been mainly attributed to their anti-inﬂammatory activ-
ities [18]. However, long-term treatment with antibiotics
is not well tolerated due to requiring frequent adminis-
tration, poor compliances and side eﬀects including gas-
trointestinal intolerance, photosensitivity, and candidiasis
[19].
Azithromycin is eﬀective in treating rosacea. Facial skin
biopsies were taken from 17 subjects with papulopustular
rosacea and 25 healthy controls. Rosacea patients had
greater skin reactive oxygen species levels than healthy
controls (P<0.001). Rosacea subjects then received oral
azithromycin 500mg on three days each week for 4 weeks.
A statistically signiﬁcant decrease in chemiluminescence,
a measurement of the generation of reactive oxygen
species, was demonstrated after treatment with azithromycin
[19].
The utility of oral azithromycin was conﬁrmed by several
other clinical studies. Fernandez-Obregon [20] reported that
all of ten patients who were not tolerated or controlled by
conventionaltreatmentofrosaceademonstratedasigniﬁcant
improvement with the oral use of azithromycin. In addition,
Modi et al. [21] treated a 67-year-old man who had photo-
sensitivity to the doxycycline and hyperpigmented dyschro-
mia to the minocycline with an oral use of azithromycin in a
dose of 250mg 3 times weekly. Bakar et al. [19] reported that
treatment with oral azithromycin led to 75% decreases in the
totalnumberoflesionsandan89%decreaseininﬂammatory
lesionscomparedwithbasalstatus.Anotheropen-labelstudy
showed that azithromycin is as eﬀective as standard dose of
doxycycline and has a positive impact on the quality of life
of patients compared with conventional treatment regimens
[22].
Kim et al. [23] treated a 52-year-old woman who had
intractable rosacea not responding to various conventional
treatments including topical benzoyl peroxide and metron-
idazole as well as oral metronidazole, isotretinoin, and
doxycycline, by using oral azithromycin 500mg per day
for 2 weeks. The authors reported that the lesions had
mostly disappeared, and no speciﬁc side eﬀects related to the
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(B) Macrolides and Adult-Onset Still’s Disease (AOSD).
Adult-onset Still’s disease (AOSD), an autoinﬂammatory
syndrome of unknown etiology, typically manifests with
spiking fevers, polyarthritis, and characteristic evanescent
rash. Thanou-Stavraki et al. [24] described a young woman
with AOSD complicated by calf fasciitis that serendipi-
tously responded to clarithromycin administered for another
indication. Remarkable improvement followed rechallenges
with clarithromycin for subsequent AOSD ﬂares. Although
AOSD pathogenesis remains unclear, a role for dysregulation
of innate immunity is suggested. Based on this possible
innate immune mechanism, the investigators suspected that
macrolides may have induced a therapeutic response in this
patient with AOSD.
Saviola et al. [25] treated six cases of AOSD with
clarithromycin (CM) in combination with low-mild dose
of glucocorticoids (GC), and methotrexate (MTX). Four of
them were not responsive to high-dose GC added to disease-
modifying antirheumatic drugs (DMARDs), while two of
them were treated with low-mild dose of GC added to CM
from the beginning. CM, 500mg b.i.d., was added to a
mild-low dose of GC and to MTX. The dose of the drugs
was reduced (and stopped where possible) following clinical
and laboratory parameters. ACR criteria were used to assess
clinical improvement. At 6 months, 5 patients reached ACR
70%andcouldstopanytherapyin6–18months;1continued
chronictherapywithlow-doseGCaddedtoCMandMTXto
maintain ACR 50%. The authors reported that CM can be a
useful drug for the treatment of AOSD, even in patients not
responsive to high-dose GC and DMARDs.
(C) Macrolides and SAPHO Syndrome. In 1987, synovitis,
acne, pustulosis, hyperostosis, and osteitis (SAPHO) syn-
drome was proposed as an umbrella term for a group
of diseases with similar musculoskeletal manifestations, in
particular hyperostosis of anterior chest wall, synovitis, and
multifocalasepticosteomyelitis,observedinassociationwith
dermatologic conditions such as palmo-plantar pustulosis,
severe acne, and hidradenitis suppurativa [26]. Despite
recent advances in the understanding of the epidemiologic,
pathophysiologic, and immunogenetic mechanisms involved
in SAPHO syndrome, etiopathogenesis remains poorly
understood. Propionibacterium acnes, the microorganism
associated with acne, has been recovered on bone biopsy
in some patients, but the possible pathogenetic role of
an infectious agent in a genetically predisposed individual,
resulting in exaggerated inﬂammatory response as “reactive
osteitis,” is a largely unproven hypothesis [27].
Schaeverbeke and colleagues reported one case of suc-
cessful treatment of a SAPHO patient with azithromycin
[28]. Kirchhoﬀ and colleagues presented data for seven
patients being treated successfully with azithromycin over
5 months [29]. Assmann et al. [30] reported successful
control of the disease with azithromycin over 16 weeks.
Afterantibioticdiscontinuation,however,diseaserelapsewas
observed.
Matzaroglou et al. [31] reported ﬁve patients with
SAPHO syndrome (3 women; 2 men), ages 27 to 44 years,
showed remarkable response to treatment with macrolide
antibiotic (clindamycin) and nonsteroid anti-inﬂammatory
drugs (lornoxicam). All patients did well and remained
symptom-free for up to four years, after a 3–8-month
course of treatment. The authors concluded that appropriate
therapy with antibiotics and NSAIDs can produce rapid
symptom resolution, while avoiding unnecessary procedures
and long-term antibiotic therapy.
(D) Macrolides and Psoriasis. Psoriasis is a well-known
clinical description of an inﬂammatory skin disorder with
other manifestations of what, until now, has been considered
as a single disease entity. The characteristic skin lesion
is persistent, erythematous, indurated and scaly, reﬂecting
inﬁltration of inﬂammatory cells and increased proliferation
and turnover of keratinocytes. The inﬁltrates in the dermis
and the deeper layer of the epidermis mostly comprise
of macrophages and T cells. Stimulation of dendritic cells
and macrophages, which are called antigen-presenting cells,
results in the activation of T-helper (Th) cells. These
diﬀerentiate into IFN-gamma, producing Th 1 cells, and
IL-17, producing Th 17 cells. Interaction of these cells
with macrophages, mast cells, and neutrophils results in
cytokine release and inﬂammation, leading to keratinocyte
proliferation [32].
Psoriasis is characterized by the presence of neutrophil
overactivation and overproduction of interleukin (IL)-6
and IL-8 from keratinocytes [33]. Macrolide antibiotics are
widely used as antimicrobial agents. It is now clear that
macrolide antibiotics inhibit the production of many proin-
ﬂammatorycytokines,suchasIL-6,IL-8,andtumornecrosis
factor (TNF)-α, perhaps by suppressing the transcription
factors nuclear factor (NF)-κB or activator protein-1, and
reduce neutrophil activity [34]. There are conﬂicting views
in the literature regarding the eﬃcacy of macrolides on
psoriasis. Although in some studies it has been reported that
intervention by antibiotics is not beneﬁcial [35, 36], other
studies have shown eﬃcacy of macrolides in psoriasis [33].
A high incidence of streptococcal throat infection as the
main trigger for psoriasis exacerbations favors streptococcal
antigens as a causative agent, which may induce cross-
reactive T-cell responses against skin components [37, 38].
Staphylococcal superantigens have also been associated with
psoriatic disease [31].
Ohshima et al. [39] deserves special attention, where
ten patients with chronic plaque psoriasis were enrolled
and advised to take 150mg Roxithromycin (a macrolide)
orally twice daily for 1 to 7 weeks. Six out of the ten
patients exhibited a decrease in psoriasis area and severity
index (PASI) score. The mechanism by which macrolides
downregulates the host inﬂammatory response was unclear
but certainly multifactorial.
Macrolides, as a class, and azithromycin in particu-
lar, have a characteristic immunomodulatory and anti-
inﬂammatory potential, in addition to their main antibac-
terial action against streptococci. Suppression of secre-
tions of the cytokine-interleukin (IL)-8 may be important.
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events in interferon gamma-treated keratinocytes, including
expression of MHC class II, secretion of IL-1 alpha, and
superantigen presenting ability [40, 41].
Saxena and Dogra [42] tried oral azithromycin in
a single blind randomized case-control trial. 50 patients
with moderate-to-severe chronic plaque psoriasis were
enrolled. Of these, 30 randomly selected patients received
azithromycin for 48 weeks as a single oral 500mg daily
dose for 4 days with a gap of 10 days (total 24 such
courses). The remaining 20 patients received a vitamin
C tablet (nonchewable) in the same dosage schedule. A
signiﬁcant improvement in PASI score was noted from
12 weeks in the majority of patients in the azithromycin
group. At the end of 48 weeks, 18 patients (60%) showed
excellent improvement, while 6 patients (20%) showed
good improvement, and 4 patients (13.33%) showed mild
improvement. A signiﬁcant improvement in the skin lesions
was noted at 12 weeks of azithromycin therapy. Based on this
study, the authors reported that the results substantiated the
hypothesis that chronic ongoing stimulus by the streptococci
or its superantigen was indispensable in maintaining the
disease.
17 subjects participated in an open trial of macrolides
for treatment of psoriasis. Mean PASI scores dropped sig-
niﬁcantly, and itch was reduced in 11 subjects after therapy.
Thisstudyshowedthatmacrolideantibioticsmaybeeﬀective
for treatment of psoriatic skin lesion, and that they may have
antipruritic eﬀects [33].
Tamaki investigated the antipruritic eﬀects of macrolide
antibiotics in several pruritic skin diseases. They found that
in most of the patients, the drug was very eﬀective. The
reason for the antipruritic eﬀect is not known; however,
it is suggested possibly that macrolide antibiotics inhibit
productionofcytokinesorneuropeptidesthatcausepruritus
[43].
Polat et al. [44] studied patients with psoriasis. The
patients were divided into two treatment groups: one to
receive erythromycin and topical steroids and the other
only topical steroids: the ﬁrst group were treated with
erythromycin 1000mg/day and topical corticosteroids for 4
weeks, while the control group were treated only with topical
corticosteroids. The study group comprised 36 patients;
the control group comprised 24 patients. There was no
signiﬁcant diﬀerence between the baseline mean Psoriasis
Area and Severity Index (PASI) of the two groups. They
reported that the treatment used for the study group was
more eﬀective against pruritus than that used for the control
group. Six patients with severe pruritus and six patients
with moderate pruritus in the study group found that itch
disappeared completely after the treatment. In the control
group, none of the patients with severe or moderate pruritus
found that itch disappeared completely.
(E) Macrolides and Alopecia Areata, Associated with H. pylori
Infection. Campuzano-Maya [45]d e s c r i b e dac a s eo fa4 3 -
year-old man with patchy alopecia areata and H. pylori infec-
tion;thepatienthadhairregrowthafterbacterialeradication.
The patient was prescribed ﬁrst-line H. pylori eradication
with proton pump inhibitor (omeprazole) 20mg twice daily,
amoxicillin 1000mg twice daily, and clarithromycin 500mg
twice daily for 14 days and was followed photographically
every 2wks. He was instructed not to take or apply any
medications for alopecia areata. The patient’s condition
started to improve within 4wks of completing H. pylori
eradication. By week 16, the patient had completely reversed
the hair loss, and by week 44, he remained H. pylori-
negative and completely cured of alopecia areata. The author
reported that this is the ﬁrst documented case of reversed
hairlossafterH.pylorieradicationand,ifsuchanassociation
is conﬁrmed by epidemiological studies designed for this
purpose,newtherapeuticoptionscouldbeavailableforthese
patients, especially in areas where infection with H. pylori is
highly prevalent.
(F) Macrolides and Chronic Urticaria, Associated with H.
pylori Infection. Chronic urticaria is one of the most fre-
quent skin diseases in medical practice. Urticaria is deﬁned
as acute if the whealing persists for less than six weeks and
as chronic if it persists for longer. Chronic urticaria that
lasts from several years to decades signiﬁcantly impairs the
quality of life. There is evidence that Helicobacter pylori has a
critical role in diﬀe r e n te x t r a g a s t r i cd i s e a s e ss u c ha sc h r o n i c
urticaria. Ben Mahmoud et al. [46] presented a case of
chronic urticaria in an adult patient with H. pylori infection
and disease regression after triple anti-H. pylori therapy. In
contrasttotheautoimmunemechanismsinvolvedinchronic
urticaria against which no speciﬁc treatment strategy has
been developed, infections with H. pylori could be treated
with triple therapy. The authors suggested that laboratory
tests for the detection of this pathogen should be performed
in patients with chronic urticaria.
(G) Macrolides and Pityriasis Rosea. Sharma et al. [47]
performed a clinical study to evaluate the eﬃcacy of
erythromycin in patients with pityriasis rosea (PR). Ninety
patientsoveraperiodof2yearswerealternativelyassignedto
treatment group or placebo group. Patients in the treatment
group received erythromycin in divided doses for 14 days.
The response was categorized as complete response, partial
response, or no response. Complete response was observed
in 33 patients (73.33%) in the treatment group and none
in the placebo group. The authors concluded that oral
erythromycin was eﬀectivein treating patients withpityriasis
rosea, and that the eﬀect of erythromycin may be related to
its anti-inﬂammatory properties.
Rasi et al. [48] conducted a placebo-controlled study on
184 patients with pityriasis rosea attending the outpatient
dermatology department clinic. Adult patients were treated
with200mgoferythromycin4timesdaily,andchildrenwere
treatedwith20to40mg/kgdailyin4divideddoses.Controls
were given a placebo (an emollient cream) that was not
identicalinappearance.Subjectswereseenatfollow-upvisits
2, 4, 6, and 8 weeks after starting treatment. Both groups
were comparable with regard to sex, age, and mean duration
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no signiﬁcant diﬀerence between the 2 treatment groups at
weeks 4, 6, and 8 after beginning of treatment.
Other authors believe that the use of macrolides is best
considered experimental and should not be adopted into
routine clinical practice until further studies are conducted
and results are published. Even if macrolides are ﬁnally
proven to be eﬀective in modifying the course of PR, this
does not substantiate that PR is caused by a bacterial rather
than a viral infection. Macrolides have anti-inﬂammatory
and immunomodulating eﬀects that might aﬀect the course
of PR or other cutaneous eruptions independent of their
antibacterial properties [49].
(H) Macrolides and Pityriasis Lichenoides. Pityriasis liche-
noides is an uncommon reactive papulosquamous erup-
tion of unknown origin. Truhan et al. [50]p e r f o r m e da
study to determine the eﬀects of erythromycin in pityriasis
lichenoides. Fifteen of twenty-two children with pityriasis
lichenoides were treated with oral erythromycin. Eleven
(73%) had a remission, usually within 2 months. Two others
showed partial improvement, and two were unimproved.
Seven of the children who experienced a remission were
oﬀ erythromycin and free of lesions after 2 to 5 months of
therapy. The authors concluded that a trial of erythromycin
should be considered in children with pityriasis lichenoides
before other, possibly more toxic, measures are instituted.
Skinner and Levy [51] reported two cases of persis-
tent pityriasis lichenoides et varioliformis acuta (PLEVA)
unresponsive to tetracycline and erythromycin that rapidly
resolved with bimonthly treatment with azithromycin for
5 days. The ﬁrst case was a 51-year-old female started on
azithromycin 500mg on day 1 and 250mg on days 2 through
5, to be taken on the ﬁrst and third weeks of the month.
One week after starting the ﬁrst course, she reported that no
new lesions had formed, and that the current lesions were
resolving. After 3 weeks and two courses of azithromycin,
the patient was clear of all lesions. She has remained clear
for 6 months. The second case was a 5-year-old boy in whom
erythromycin taken for 3 months did not improve the rash.
Hewasthenstartedonthesameazithromycinregimenstated
above. Eight weeks later, the patient had completed four
courses of azithromycin. He had marked improvement, with
only a few remaining smooth papules. He was continued on
azithromycin for one more course and was clear of all lesions
on 1-month followup and again 2 months later.
(I) Macrolides and Bullous Pemphigoid. Bullous pemphigoid
is the most common autoimmune-mediated bullous disease
in men. Mensing and Krausse [52] tested erythromycin
combined with a low-dose methylprednisolone in eleven
patients in a prospective study. A historical collective of the
last 33 patients treated before this study was started served
as the control group. The duration of hospitalization as
an expression of therapeutic response, but also of lowered
side eﬀects dropped down from 43 to 33 days in the
erythromycin treated group. Altomare et al. [53]r e p o r t e d
that the macrolide antibiotic erythromycin has been eﬀective
in bullous pemphigoid in their studied patients. Fox et al.
[54] reported two patients with bullous pemphigoid treated
with erythromycin demonstrated improvement.
(J) Successful Treatment of Idiopathic Thrombocytopenic Pur-
pura with Macrolides. Ohe and Hashino [55]r e p o r t e d3
cases of primary immune thrombocytopenia (ITP) patients
whoweresuccessfullytreatedwithmacrolides,irrespectiveof
Helicobacter pylori (H. pylori) infection status. Case 1, an 88-
year-old woman who was an H. pylori-positive ITP patient,
was treated with clarithromycin (CAM). CAM was eﬀective
temporarily. As an alternative to CAM, she was successfully
treated with erythromycin (EM) for more than 7 months.
Case 2, a 61-year-old man who was an H. pylori-negative
ITP patient, was unsuccessfully treated with CAM but
successfully treated with EM. Case 3, a 75-year-old woman
who was a H. pylori-negative ITP patient, was treated with
CAM. CAM was eﬀective temporarily. After approximately 6
months, she was treated with EM for a common cold, and
her platelet count increased rapidly. The authors concluded,
based on these ﬁndings, that macrolide treatment was
eﬀective for ITP. The eﬀectiveness of macrolides might
suggest immunomodulatory eﬀects as well as antibacterial
eﬀects for H. pylori.
In a previous work, the authors have already reported
3 cases of idiopathic thrombocytopenic purpura (ITP), also
known as primary immune thrombocytopenia, which show
increasedplateletcountsfollowingclarithromycintreatment,
irrespective of H. pylori infection status [56].
The authors attributed this therapeutic success of
macrolides in treating cases of ITP to the immunomodula-
tory eﬀects of macrolides. Immunomodulatory eﬀects from
macrolideantibioticsmightbeobtainedbytheeradicationof
bacteria or by modulation of the immune system involving
the mucosa on which commensal bacteria reside [57].
2. Conclusion
Despite the small number of studies shedding light on the
anti-inﬂammatory and immunomodulatory mechanisms of
the macrolides, there is strong evidence providing support
to the beneﬁt of using this type of drug for the long
term and in low doses to treat some chronic inﬂammatory
skin disorders. The macrolides have some potentially useful
immunomodulatory eﬀects. Although additional studies are
needed, macrolide therapy in some of chronic dermatoses
has the potential of modifying the morbidity and possibly
ameliorating the severity of some, but not all, of these
conditions. Further well-designed, adequately powered ran-
domized controlled trials are required.
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